Skip to content

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF 6-DAY ORAL TR-701 FREE ACID AND 10-DAY ORAL LINEZOLID FOR THE TREATMENT OF ACUTE BACTERIAL SKIN INFECTIONS AND SKIN STRUCTURE

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF 6-DAY ORAL TR-701 FREE ACID AND 10-DAY ORAL LINEZOLID FOR THE TREATMENT OF ACUTE BACTERIAL SKIN INFECTIONS AND SKIN STRUCTURE

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-008-11
Enrollment
60
Registered
2011-02-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

APPROXIMATELY 130 SITES GLOBALLY WILL PARTICIPATE IN THIS STUDY. APPROXIMATELY 658 PATIENTS WITH AN ABSSSI CAUSED BY SUSPECTED OR DOCUMENTED GRAM-POSITIVE PATHOGEN(S) AT BASELINE WILL BE RANDOMIZED 1:

Sponsors

TRIUS THERAPEUTICS, INC,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.MALES OR FEMALES ≥ 18 YEARS OLD 2.ABSSSI MEETING AT LEAST 1 OF THE CLINICAL SYNDROME DEFINITIONS LISTED BELOW AND REQUIRING SYSTEMIC ORAL ANTIBIOTIC THERAPY. LOCAL SYMPTOMS MUST HAVE STARTED WITHIN 7 DAYS BEFORE THE SCREENING VISIT. A.CELLULITIS/ERYSIPELAS DEFINED AS A DIFFUSE SKIN INFECTION, CHARACTERIZED BY ALL OF THE FOLLOWING WITHIN 24 HOURS: • RAPIDLY SPREADING AREAS OF ERYTHEMA OF A MINIMUM SURFACE AREA OF 75 CM² • NO COLLECTION OF PUS APPARENT UPON VISUAL EXAMINATION (DIAGNOSIS STILL CONSISTENT WITH CELLULITIS/ERYSIPELAS IF PUS IS COLLECTED FROM THE LESION) • AT LEAST 1 OF THE FOLLOWING SIGNS OF INFECTION: O INDURATION O LOCALIZED WARMTH O PAIN OR TENDERNESS ON PALPATION O SWELLING • AT LEAST 1 OF THE FOLLOWING SYSTEMIC SIGNS OF INFECTION: O LYMPH NODE TENDERNESS AND INCREASE IN VOLUME OR PALPABLE PROXIMAL TO THE PRIMARY ABSSSI O FEVER, DEFINED AS BODY TEMPERATURE ≥ 38°C (101.2°F) ORAL, ≥ 38.5°C (101.2°F) TYMPANIC, OR ≥ 39°C (102.2°F) RECTAL (OBSERVED BY A HEALTH CARE PROVIDER) O WBC COUNT ≥ 10,000 CELLS/MM³ OR 10% IMMATURE NEUTROPHILS

Exclusion criteria

Exclusion criteria: 1. UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (SSSIS) SUCH AS FURUNCLES, MINOR ABSCESSES (AREA OF SUPPURATION NOT SURROUNDED BY CELLULITIS/ERYSIPELAS), IMPETIGINOUS LESIONS, SUPERFICIAL OR LIMITED CELLULITIS/ERYSIPELAS, AND MINOR WOUND INFECTIONS (EG, STITCH ABSCESSES) 2. INFECTIONS ASSOCIATED WITH, OR IN CLOSE PROXIMITY TO, A PROSTHETIC DEVICE 3. SEVERE SEPSIS OR SEPTIC SHOCK 4. KNOWN BACTEREMIA 5. ABSSSI DUE TO OR ASSOCIATED WITH ANY OF THE FOLLOWING: O SUSPECTED OR DOCUMENTED GRAM-NEGATIVE PATHOGENS IN PATIENTS WITH CELLULITIS/ERYSIPELAS OR MAJOR CUTANEOUS ABSCESS THAT REQUIRE AN ANTIBIOTIC WITH SPECIFIC GRAM-NEGATIVE COVERAGE. PATIENTS WITH WOUND INFECTIONS WHERE GRAM-NEGATIVE ADJUNCTIVE THERAPY IS WARRANTED MAY BE ENROLLED IF THEY MEET THE OTHER ELIGIBILITY CRITERIA O DIABETIC FOOT INFECTIONS, GANGRENE, OR PERIANAL ABSEESS O CONCOMITANT INFECTION AT ANOTHER SITE NOT INCLUDING A SECONDARY ABSSSI LESION (EG, SEPTIC ARTHRITIS, ENDOCARDITIS, OSTEOMYELITIS) O INFECTED BURNS O DECUBITUS OR CHRONIC SKIN ULCER, OR ISCHEMIC ULCER DUE TO PERIPHERAL VASCULAR DISEASE (ARTERIAL OR VENOUS) O ANY EVOLVING NECROTIZING PROCESS (IE, NECROTIZING FASCIITIS) O INFECTED HUMAN OR ANIMAL BITES O INFECTIONS AT VASCULAR CATHETER SITES OR INVOLVING THROMBOPHLEBITIS

Countries

Croatia, Czech Republic, Hungary, India, Mexico, Poland, Romania, Ukraine, United States

Contacts

Public ContactElizabeth Beatriz Rospigliosi

I3 LATIN AMERICA PERU S.A.

elizabeth.rospigliosi@i3research.com6164102

Outcome results

None listed

Source: REPEC (via WHO ICTRP)